Effectiveness and Safety of Batroxobin, Tranexamic Acid and a Combination in Reduction of Blood Loss in Lumbar Spinal Fusion Surgery
| Autor: | Rishi Mugesh Kanna, Srikanth Reddy Dumpa, Rajasekeran Shanmuganathan, Balavenkat Subramanian, Roopa M Nagabhushan, Ajoy Prasad Shetty |
|---|---|
| Rok vydání: | 2018 |
| Předmět: |
Adult
Male medicine.medical_specialty Blood transfusion Anemia medicine.medical_treatment Deep vein Blood Loss Surgical Postoperative Hemorrhage Hematocrit 03 medical and health sciences 0302 clinical medicine Double-Blind Method Fibrinolytic Agents medicine Humans Blood Transfusion Orthopedics and Sports Medicine Prospective Studies Aged Lumbar Vertebrae medicine.diagnostic_test business.industry Batroxobin Perioperative Middle Aged medicine.disease Thrombosis Antifibrinolytic Agents Surgery Spinal Fusion Treatment Outcome medicine.anatomical_structure Tranexamic Acid 030220 oncology & carcinogenesis Anesthesia Drug Therapy Combination Female Neurology (clinical) business 030217 neurology & neurosurgery Tranexamic acid medicine.drug |
| Zdroj: | Spine. 43:E267-E273 |
| ISSN: | 1528-1159 0362-2436 |
| DOI: | 10.1097/brs.0000000000002315 |
| Popis: | STUDY DESIGN A prospective randomized double blind placebo controlled trail. OBJECTIVE To evaluate and compare the efficacy and safety of batroxobin (botropase), tranexamic acid (TXA), and their combination in reduction of perioperative blood loss in lumbar spine single level fusion surgeries. SUMMARY OF BACKGROUND DATA Spinal surgeries are associated with significant blood loss leading to perioperative anemia and increased need for allogenic transfusion. TXA competitively inhibits plasmin and batroxobin converts fibrinogen to fibrin and theoretically their combination is synergistic. Though TXA is widely studied in controlling blood loss, there is little information on use of batroxobin and their combination. Thus, we aimed to study effect and safety of individual drugs and their combination in controlling blood loss in spinal surgery. METHODS Hundred patients were randomized into four groups. Group B received batroxobin, group T received TXA, group BT received batroxobin and TXA and group P received placebo. Outcomes assessed are intraoperative and postoperative blood loss, hematocrit, allogenic blood transfusion, and deep vein thrombosis (DVT), postoperatively. RESULT Mean intraoperative blood loss in Group B, T, BT, and P were 268.32 ± 62.92 mL, 340.72 ± 182.75 mL, 256.96 ± 82.64 mL, and 448.44 ± 205.86 mL, respectively. Postoperative surgical site drain collection in Group B, T, BT, and P were 218.00 ± 100.54 mL, 260.40 ± 100.85 mL, 191.00 ± 87.84 mL, and 320.00 ± 125.83 mL, respectively. Intraoperative blood loss of Group P was statistically higher than Groups B and BT (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|